Article Text

PDF
SAT0376 Serum CRP Levels Demonstrate Predictive Value for Radiographic and MRI Outcomes in Patients with Active as Treated with The TNF-Inhibitor Golimumab
  1. J. Braun1,
  2. X. Baraliakos1,
  3. K.-G. Hermann2,
  4. S. Xu3,
  5. B. Hsu3
  1. 1Rheumazentrum Ruhrgebiet, Herne
  2. 2Charité Universitätsmedizin, Berlin, Germany
  3. 3Janssen R & D, LLC, Spring House, United States

Abstract

Background While the introduction of anti-tumor necrosis tumor (TNF) biologic agents can significantly improve signs/symptoms of ankylosing spondylitis (AS) and reduce magnetic resonance imaging (MRI)-detected spinal inflammation, the effect of such therapy on future radiographic progression is less clear. Serum C-reactive protein (CRP) associates with radiographic progression in AS patients untreated with TNF-antagonists.

Objectives We assessed correlations between serum CRP after 2 years of anti-TNF therapy and radiographic progression/inflammation in the GO-RAISE trial.

Methods Active AS patients receiving golimumab/placebo through week-16 (early-escape) or week-24 (crossover by design), followed by golimumab through 4 years, had sera/images obtained through week 208. Lateral spinal radiographs and spinal MRIs were scored using the modified Stoke AS spine score (mSASSS) and AS spinal MRI activity (ASspiMRI-a) score, respectively. Analyses of variance assessed differences based on CRP levels and mSASSS progression. The relationships between CRP levels and mSASSS/ASspiMRI-a score were assessed by Spearman correlation and logistic regression.

Results 299/356 (84.0%) randomized GO-RAISE patients had spinal radiographs available at both timepoints. Larger proportions of patients with week-104 CRP ≥0.5mg/dL (n=47) vs. <0.5mg/dL (n=236) (40.4% vs. 22.9%; p=0.0121) had mSASSS changes ≥2 at week-104 (Figure). Across several visits, serum CRP demonstrated weak associations with mSASSS change (rs= -0.33–0.54; p<0.05; n=65–89). Higher baseline CRP was associated with increased risk for syndesmophytes at week-104/week-208, while large decreases in CRP from baseline to week-14/week-24 yielded decreased risk of new bone formation (Figure 1).

Conclusions This is the first study to show that CRP level is not only a useful marker at baseline of the initiation of anti-TNF therapy but also at follow up examinations. Thus, elevated CRP after 2 years of anti-TNF treatment correlated with greater radiographic progression risk at 4 years. Intermittent measurements of serum CRP weakly predicted subsequent radiographic progression and modestly predicted residual spinal inflammation in anti-TNF treated AS patients. Thus, incomplete suppression of inflammation in AS patients may be a relevant factor for new bone formation, and serum CRP appears to be a pertinent predictive biomarker for long-term AS progression among patients receiving TNF-antagonists. It is possible that higher doses of anti-TNF agents are necessary for patients with persistently elevated CRP values to prevent new bone formation more effectively.

Disclosure of Interest J. Braun Grant/research support from: Janssen R & D, LLC, X. Baraliakos Grant/research support from: Janssen R & D, LLC, K.-G. Hermann Grant/research support from: Janssen R & D, LLC, S. Xu Employee of: Janssen R & D, LLC, B. Hsu Employee of: Janssen R & D, LLC

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.